Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01072448 · ClinicalTrials.gov registry record · Phase 3

12-week Efficacy of Indacaterol

A Phase 3 study, sponsored by Novartis.

Completed
Registry status
Phase 3
Development phase
323
Enrollment target

NCT01072448 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 323 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01072448, a Phase 3 study, has completed, sponsored by Novartis.

COMPLETED
Registry status
Phase 3
Development phase
323 participants
Enrollment target

Study Summary

This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.

Interventions

  • DRUG Placebo to indacaterol
  • DRUG Indacaterol 75 μg

Trial Details

FieldValue
Enrollment Target 323 participants
Start Date 2010-01
Est. Completion 2010-07
Phase Phase 3

Sponsor

Novartis

265 total trials

What the Registry Record Tells You About NCT01072448

The ClinicalTrials.gov registry entry for NCT01072448 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo to indacaterol is the first listed.

NCT01072448 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01072448 about?

NCT01072448 is a clinical study titled "12-week Efficacy of Indacaterol". This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.

What is the current status of trial NCT01072448?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 323 participants. The study started on 2010-01. Estimated completion is 2010-07.

What interventions are being tested in trial NCT01072448?

The interventions under investigation include: Placebo to indacaterol (DRUG), Indacaterol 75 μg (DRUG).

Who is sponsoring clinical trial NCT01072448?

This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.